Tag: Cancer Drugs

Daiichi Sankyo Announced Launch of VANFLYTA® in Japan

Daiichi Sankyo Company, Limited announced the launch of VANFLYTA® (quizartinib), an oral FLT3 inhibitor, in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid le...

Eli Lilly Announced Positive Results from Phase 3 RELAY trial of CYRAMZA®

Eli Lilly and Company announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSC...

NICE Refused to Recommend Tecentriq by Roche for Triple Negative Breast Cancer Treatment

Draft guidance published by NICE does not recommend atezolizumab, Tecentriq by Roche, for treating people with a type of breast cancer that has spread to other parts of the body. Atezolizumab, give...

Eisai and Merck Announced Final Results from Study Evaluating LENVIMA plus KEYTRUDA

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 e...

Servier Announced Acquisition of PIXUVRI® from CTI BioPharma

Servier, an independent international pharmaceutical company, announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory a...

Roche Presented Positive Results from Phase III IMvigor130 Study Evaluating Tecentriq®

Roche presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatm...

AstraZeneca and Merck’s LYNPARZA® Phase 3 PAOLA-1 Trial Presented

astrazeneca
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced detailed positive results from the Phase 3 PAOLA-1 trial showing LYNPARZA added to bevacizumab demonstrated a statis...

GSK Announced Results from PRIMA Study of Zejula

gsk
GlaxoSmithKline plc announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with firs...

Amgen Announced Positive Results from Two Clinical Trials Phase 3 BLINCYTO®

Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free ...

European Commission Granted Marketing Authorization for Bayer Vitrakvi®

Bayer
Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi® (larotrectinib). The drug is indicated for...

Ipsen Registered New Anticancer Drug in Russia

Ipsen announced the registration of a new anticancer drug in Russia, cabosantinib. The drug is intended for the treatment of advanced renal cell carcinoma (RCC) in adult patients with intermediate or ...

FDA Approved ERLEADA® for Metastatic Castration-Sensitive Prostate Cancer Treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastat...

FDA Approved Merck’s Lenvima Under New Project Orbis

The U.S. Food and Drug Administration is announcing Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review...

FDA Granted Priority Review for Enfortumab Vedotin BLA for Urothelial Cancer Treatment

astellas
Seattle Genetics, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab...

FDA Warned that Three Breast Cancer Drugs May Cause Severe Inflammation of Lungs

cancer treatment
The US Food and Drug Administration (FDA) warned that breast cancer drugs, Ibrance (palbociclib) from Pfizer, Novartis' Kisqali (ribociclib) and Lilly's Verzenio (abemaciclib) may cause rare but sever...

Teva and FSUE “Moscow Endocrine Plant” to Introduce Trizenox on Russian Market

On September 16, 2019, as part of the IV annual BIOTECHMED Biotechnology Forum, Teva and FSUE “Moscow Endocrine Plant” signed a Memorandum of Intent to implement actions aimed at introducing the Trize...